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Abstract 
Drug abuse is a global problem of considerable concern to health.  One such health concern 
stems from the fact that many drugs of abuse have immunosuppressive actions, and 
consequently have the potential to increase susceptibility to infectious disease.  This article is 
focused on the impact of the amphetamine derivative methylenedioxymethamphetamine 
(MDMA; “Ecstasy”) on immunity.  Research conducted over the last five years has 
demonstrated that MDMA has immunosuppressive actions, in both laboratory animals and 
humans.  Specifically, MDMA suppress neutrophil phagocytosis, suppresses production of the 
pro-inflammatory cytokines TNF- and IL-1 and increases production of an endogenous 
immunosuppressive cytokine IL-10, thereby promoting an immunosuppressive cytokine 
phenotype.  MDMA also suppresses circulating lymphocyte numbers, with CD4+ T-cells being 
particularly affected, and alters T-cell function as indicated by reduced mitogen stimulated T-
cell proliferation, and a skewing of T-cell cytokine production in a Th2 direction.  For the most 
part the aforementioned effects of MDMA are not due to a direct action of the drug on immune 
cells, but rather due to the release of endogenous immunomodulatory substances. 
Consequently, the physiological mechanisms that are thought to underlie the 
immunosuppressive effects of MDMA will be discussed.  As many of the physiological 
changes elicited by MDMA closely resemble those induced by acute stress, it is suggested that 
exposure to MDMA could be regarded as a “chemical stressor” on the immune system.  
Finally, the potential of MDMA-induced immunosuppression to translate into significant health 
risks for abusers of the drug will be discussed.  
Keywords: MDMA, Drug abuse, Immunity, Cytokine, T-Cell, Macrophage, NK-cell. 
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Introduction  
Drug abuse is a worldwide problem that has major social, health and economic implications.  
Over the last two decades investigators have documented the ability of a number of drugs of 
abuse such as cocaine, opioids, cannabinoids and amphetamines to impair many aspects of 
immune function, either directly, or via neuroimmune pathways [1-6].  In addition, there is 
substantial evidence that the stress associated with morphine and cocaine withdrawal also 
induces an immunosuppressive state [7,8].  Moreover, numerous reports indicate that the 
immunosuppression elicited by drugs of abuse can result in diminished host resistance to 
disease in a number of experimental models [9-12].  Indeed some investigators have implicated 
drug abuse as a co-factor in susceptibility to infection with HIV or other viruses [10,11,13,14].  
This review focuses on the immunomodulatory capacity of methylenedioxymethamphetamine 
(MDMA; “Ecstasy”), an amphetamine-derivative that has become a popular drug of abuse over 
the last two decades [15,16].   
 
MDMA – History and biological actions 
MDMA is a ring-substituted phenylisopropylamine that is structurally related to both 
amphetamines and hallucinogens.  The compound was initially developed as an appetite 
suppressant in 1914 by Merck Pharmaceuticals, but was never marketed for this purpose.  It 
was later discovered that MDMA had psychoactive properties, and it was reported to confer 
benefit as an adjunct to psychotherapy, where it was shown to enhance communication and 
intimacy [16].  In the 1980’s MDMA became a popular drug of abuse, particularly at raves and 
all night dance clubs.  However, following an increase in the prevalence of it’s abuse, and 
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evidence of adverse health effect’s MDMA was classified as a schedule I controlled substance 
by the FDA in 1985.   
  
In terms of its neurochemical mechanism of action, MDMA is a potent releaser of the 
indolamine neurotransmitter serotonin, and to a lesser extent the catecholamine 
neurotransmitter dopamine in the central nervous system (CNS) [17,18]. These neurochemical 
actions of MDMA result in psychoactive properties that have been studied both in animals and 
humans [19-21].  In humans, MDMA produces a relaxed, euphoric state, including emotional 
openness, increased empathy and a decrease in inhibitions.  These subjective behavioural 
effects elicited by MDMA have led to its widespread abuse over the last 15-20 years [see 15]. 
 
Figure 1: An illustration of the chemical structures of (A) Amphetamine and Methamphetamine, both 
of which stimulate catecholamine release in the CNS, and (B) MDA, MDMA, MDEA and fenfluramine; 
substituted amphetamines all of which are potent releasers of serotonin 
 
In addition to the psychoactive properties of MDMA, it produces an array of physiological 
actions such as hyperthermia, acute sympathomimetic effects, such as increased heart rate and 
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blood pressure, a transient increase in anxiety, and increased activation of the hypothalamic 
pituitary adrenal axis as indicated by increased circulating glucocorticoid concentrations [see 
15].  Experimental studies conducted in laboratory animals [22,23] and humans [21] have 
concluded that many of these actions of MDMA occur secondary to central release of either 
serotonin or dopamine.   
 
MDMA use has been associated with a number of serious side effects, such as cardiac 
arrhythmias, hyperthermia, renal failure, seizures and intracranial hemorrhage [see 15,16]. In 
addition, to these acute toxic effects there is substantial evidence that MDMA can result in 
long-term neurotoxic effects on central serotonergic neurons [24,25], and that this may 
represent a predisposing factor to psychological disturbances/psychiatric disease [see 26]. 
 
In the last number of years it has become evident that, like other drugs of abuse, MDMA has 
immunosuppressive properties. A number of studies indicate that MDMA suppresses aspects of 
both innate and adaptive immunity in laboratory animals [27-34] and in humans [35-39].  In the 
remainder of this review I will discuss the evidence that MDMA impacts upon immune 
function, discuss the potential mechanisms by which MDMA elicits it’s immunomodulatory 
actions, and also discuss the potential of MDMA-induced immunosuppression to translate into 
significant health risks for abusers.  
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Figure 2: A diagrammatic summary of the effect of in vivo administration of MDMA on 
aspects of innate and adaptive immunity.
Please use the following citation: O’Connor TJ (2004) Methylenedioxymethamphetamine (MDMA “Ecstasy”): A stressor on the 
immune system, (Author postprint) in Immunology, 111(4), 357-367 [Accessed: (date) from www.drugsandalcohol.ie] 
7
Table 1: A summary of the studies conducted concerning the impact of MDMA on the 
immune system 
Parameter Source Stimulant MDMA Conc./Dose Effect Ref. 
Neutrophil phagocytosis Rat blood Zymosan In vivo: 10 mg/kg (i.p.)/ In vitro (10 
g/ml) 
Decrease [28] 
IL-1  production Rat blood LPS In vivo: 10-20 mg/kg (i.p.)  Decrease [30,31] 
Rat blood LPS In vitro: 1-10 g/ml No change [31] 
Human blood PHA In vivo: 100 mg (p.o) Decrease [38] 
TNF-production Rat blood LPS In vivo: 5-20 mg/kg (i.p.)  Decrease [30,31] 
Rat blood LPS In vitro: 1-10 g/ml No change [31] 
Mouse macrophages LPS In vitro: 0.0001–100M No change [50] 
IL-6 production Mouse macrophages LPS In vitro: 0.0001–100M No change [50] 
Human blood PHA In vivo: 100 mg (p.o) Decrease [38] 
IL-10 production Rat blood LPS In vivo: 1.25-10 mg/kg (i.p.)  Increase [28] 
Rat blood LPS In vitro: 1-10 g/ml No change [28] 
Rat blood Con A In vivo: 7.5 mg/kg (i.p.)  Decrease [32] 
Human blood PHA In vivo: 100 mg (p.o) Increase [38] 
TGF-1 production Human blood PHA In vivo: 100 mg (p.o) Increase [38] 
IFN-production Rat blood Con A In vivo: 7.5 mg/kg (i.p.) Decrease [32] 
Human blood PHA In vivo: 100 mg (p.o) Decrease [38] 
Rat splenocytes KLH In vivo: 10 mg/kg (i.p.) Decrease [29] 
IL-2 production Rat blood Con A In vivo: 7.5 mg/kg (i.p.) Decrease [32] 
Human blood PHA In vivo: 100 mg (p.o) Decrease [38] 
Mouse splenocytes Anti-CD3 In vitro: 0.0001M Increase [50] 
IL-4 production Mouse splenocytes Anti-CD3 In vitro: 0.0001–100M Increase/Decrease [50] 
Human blood PHA In vivo: 100 mg (p.o) Increase [38] 
NK cell numbers Human blood None In vivo: 75-100mg (p.o) Increase [35,37-39] 
NK cell activity Mouse splenocytes None/IL-2 In vitro: 0.0001-100M Increase/Decrease [50] 
Lymphocyte numbers Rat blood None In vivo: 1.25-40 mg/kg Decrease: Lymphocytes [32,33] 
Human blood None In vivo: 75-125 mg Decrease: CD4+ T-cells [35,37-39] 
T-cell proliferation Rat blood Con A/PHA In vivo: 7.5-20 mg/kg Decrease [32-34] 
Human blood PHA In vivo: 75-125 mg Decrease [39] 
CTL activity Mouse splenocytes None In vitro: 100M Decrease [50] 
B-cell proliferation Mouse splenocytes Anti-IgM/IL-
4 
In vitro: 0.0001-100M No change [50] 
Antibody Production Rat blood KLH In vivo: 5-10 mg/kg (i.p.) IgG2a: Decrease [29] 
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In vivo effects of MDMA in animal models 
Innate immunity 
Neutrophils are a subset of phagocytic cells that play a key role in the innate immune response.  
Neutrophil activation that occurs following phagocytosis is accompanied by an oxidative burst 
that produces reactive oxygen species, and destroys bacteria and fungi.  Administration of 
MDMA (10 mg/kg) to rats has been shown to suppress the neutrophil oxidative burst in 
response to opsonised zymosan (a phagocytic stimulus), but not in response to chemical 
stimulation of protein kinase C using the phorbol ester PMA [27].  The fact that the PMA-
induced oxidative burst was unaltered, suggests that the inhibitory effect of MDMA occurs 
upstream of protein kinase C activation, possibly by interfering with the phagocytic process.  It 
is suggested that MDMA may down regulate the expression of molecules such as CR3 or FcR 
that are required to initiate phagocytosis of opsonized zymosan, however further studies are 
required in order to study the effect of MDMA on the expression of such cell surface 
molecules. 
 
Cells of the innate immune system such as macrophages and dendritic cells produce pro-
inflammatory cytokines such as IL-1, TNF- and IL-12 in response to stimulation with 
bacterial products such as LPS.  These cytokines are of strategic importance in initiating and 
co-ordinating a large range of immune responses against invading pathogens  [see 40-43].  
MDMA administration to rats impairs the ability to respond to an in vivo immune challenge 
with bacterial lipopolysaccharide (LPS).  Specifically, MDMA suppresses LPS-induced IL-1 
and TNF- production [28,30,31]. The suppression of TNF- that occurs following MDMA 
Please use the following citation: O’Connor TJ (2004) Methylenedioxymethamphetamine (MDMA “Ecstasy”): A stressor on the 
immune system, (Author postprint) in Immunology, 111(4), 357-367 [Accessed: (date) from www.drugsandalcohol.ie] 
9
administration is the more profound and persists for longer than the suppression of IL-1 [31].  
Whilst the rat does not produce IL-12 in response to LPS (Connor et al., unpublished data), we 
have recent data demonstrating that MDMA suppresses IL-12 production in the mouse 
following an in vivo LPS challenge (Boyle and Connor, Unpublished observations). 
   
In addition, to producing pro-inflammatory cytokines, cells of the innate immune system also 
produce interleukin-10 (IL-10), an anti-inflammatory or immunosuppressive cytokine that 
inhibits several macrophage functions including pro-inflammatory cytokine production in 
response to lipopolysaccharide [44-47].  In a recent study it was demonstrated that MDMA 
provokes a dose-dependent increase in IL-10 following an in vivo LPS challenge in rats.  This 
increase in IL-10 production occurs at doses of MDMA as low as 1.25 mg/kg, and closely 
parallels the suppression of TNF- observed in response to MDMA [28].  However the ability 
of MDMA to suppress LPS-induced TNF- and IL-1 is still evident following 
immunoneutralization of IL-10, indicating that the suppression of these pro-inflammatory 
cytokines occurs independent of increased IL-10 production [28].   In addition to suppressing 
the production pro-inflammatory cytokines, IL-10 also down-regulates expression of the 
antigen presenting molecule MHC class II, and the co-stimulatory molecule B7 expression on 
antigen presenting cells, thereby inhibiting antigen presentation producing anergy in the T-cell 
arm of the immune response [45,46].  Studies are ongoing in order to determine if the increase 
in LPS-induced IL-10 production observed following MDMA administration will have a 
significant impact on the antigen presenting or co-stimulatory capacity of macrophages or 
dendritic cells.  
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Figure 3: A schematic diagram depicting the potential of MDMA-induced increases in IL-10 
production to interfere with antigen-presentation, and thereby produce anergy in the immune 
system   
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Lymphocytes are the main subset of immune cell that mediate adaptive of specific immune 
responses.  A number of studies indicate that MDMA suppresses lymphocyte function in rats.  
The first study to examine the effect of MDMA on immune function demonstrated that quite a 
high dose of MDMA (20 mg/kg, i.p.) produced a rapid (within 30 min) suppression of Con A-
induced lymphocyte proliferation, and a profound reduction in the total leucocyte count in rats 
both of which persisted for at least 6 hours following injection [34].  In a subsequent study it 
was observed that MDMA, its major metabolite MDA, and also the related amphetamine 
derivative fenfluramine, suppressed circulating lymphocyte numbers, mitogen-stimulated T-
cell proliferation and cytokine production, with MDA and fenfluramine being more potent than 
MDMA with respect to their immunosuppressive actions [32]. 
 
Whilst examining mitogen-stimulated lymphocyte responses gives a useful indication of 
lymphocyte function, it has the limitation that under normal physiological circumstances the 
immune system does not encounter mitogens, but rather encounters antigens.  Consequently a 
study was conducted to assess the impact of MDMA administration on an antigen specific 
immune response to the soluble protein antigen keyhole limpet haemocyanin (KLH) in rats 
[29].  In this study, KLH-specific immunoglobulin production and KLH-specific cytokine 
production were assessed as indices of immunocompetence.  MDMA did not alter the KLH-
specific IgM response. In contrast, MDMA (5 and 10 mg/kg) significantly suppressed KLH-
specific IgG production [29]. Therefore whilst MDMA failed to alter the initial generation of 
the antibody response, it profoundly inhibited antibody class switching from IgM to IgG. Two 
pathways for the genetic switch from IgM to IgG production were investigated. One pathway 
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requires the Th1 type cytokine IFN-  to stimulate the to IgG2a-secreting cells, whilst another 
pathway requires the Th2 type cytokines IL-4 and IL-6 to stimulate the switch to IgG1-secreting 
cells. IgG1 and IgG2a levels were measured to determine if these two pathways were 
differentially affected. The results indicate that only IgG2a levels were decreased following 
MDMA administration. Furthermore, this decrease in IgG2a production was accompanied by 
decreased KLH-specific splenic IFN-  production. Overall, these data indicate that MDMA 
alters the ability to switch from IgM to IgG2a production, possibly by reducing production of 
the TH1 cytokine IFN- .  These data indicated that in addition to the ability of MDMA to 
suppress lymphocyte response to mitogenic stimuli, that it also suppresses the Th1 arm of the 
immune response to an antigenic stimulus. 
 
In vivo effect of MDMA in humans 
Over the number of years Pacifici and co-workers have clearly demonstrated that MDMA is a 
potent immunomodulator in humans [35-39].  In these studies either placebo or MDMA (75-
100 mg) were administered orally to recreational MDMA users in a controlled setting.  The 
effect of ethanol consumption (0.8 mg/kg) on immune function was also assessed, as was the 
effect of MDMA and ethanol co-administration.  These studies were conducted double blind, 
using a crossover (Latin Square) design.  Each subject received all of the treatments in separate 
experimental sessions, with a 1-week washout period between each session.  Blood samples 
were collected from the participants at a number of time intervals up to 24 hr following drug 
administration, or up to 48 hr after drug administration in the study that assessed the impact of 
repeated doses of MDMA on immune function.   
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The first study conducted was a pilot study using four subjects.  This study demonstrated that 
MDMA profoundly suppressed the number of circulating CD4+ T-cells, suppressed mitogen 
stimulated T-cell proliferation an increased circulating numbers of NK-cells [39].  Although 
MDMA was shown to increase circulating NK-cell numbers the activity of these NK-cells was 
not assessed, consequently it is difficult to predict the effect of MDMA on overall NK-cell 
functionality.  In a follow up study the ability of MDMA to reduce the number of circulating T-
cells and increase circulating NK-cells was replicated and it was also reported that MDMA and 
promoted a switch to a Th2 type cytokine profile and indicated by reduced IFN-and IL-2 
production, with an concomitant increase in the Th2 cytokines IL-4 and IL-6, and the T-
regulatory cytokines IL-10 and TGF-1 [38].  These immunosuppressive effects of MDMA 
were maximal 3-6 hours following drug administration, and in some cases were evident 24 
hours later.  In some instances co-administration of alcohol further enhanced the 
immunosuppressive effects of MDMA.   
 
In a more recent study Pacifici and colleagues assessed cell-mediated immune responses after 
administration of two repeated doses of MDMA (100 mg per dose) at 4-hour and 24-hour 
intervals [37].  As previously reported MDMA produced a time-dependent decrease in the 
number of CD4+ T-helper cells, a decrease in the functional responsiveness of lymphocytes to 
mitogenic stimulation, and a simultaneous increase in natural killer cells. In the first clinical 
trial two MDMA doses were given 4 hours apart, and the immune changes produced by the 
first dose were enhanced following administration of the second dose.  Furthermore 
administration of two doses of MDMA 4 hours apart produced longer lasting immunological 
deficits that a single dose of MDMA; in that 24 hours after treatment, significant residual 
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effects were observed for all the altered immune parameters after the administration of two 
MDMA doses, when compared to a single dose.  In the second clinical trial, the second MDMA 
dose was administered 24 hours after the first dose, and produced immunological changes 
significantly greater than those induced by the initial drug administration, which seemed to 
show a delayed onset.  In addition, significant residual effects were observed for all the 
immune parameters as late as 48 hours after the second dose.  Based on these findings it can be 
concluded that repeated administration of MDMA with both a short and a long time interval 
between doses, increases both the magnitude and duration of MDMA-induced 
immunosuppression. 
 
The clinical trails that were outlined above were conducted in a controlled environment.  The 
same research group conduced a study in a non-controlled environment where they compared 
baseline immunological parameters in thirty recreational MDMA users that participated in their 
clinical trials, with a sample of twenty-four matched control subjects [see 36].  When baseline 
values were compared the only significant difference between MDMA users and controls was 
in NK cells numbers; with NK-cell numbers in MDMA users reduced to one-third of that seen 
in control subjects.  In another study, leucocyte subsets from six habitual MDMA users from 
the thirty that participated in the clinical trials were followed up for a two-year period, and 
compared to eight matched control subjects [see 36].   At the beginning of this study, basal 
levels of leucocyte subsets (Total lymphocytes, Thelper cells, Cytotoxic T-cells and B cells) 
were equivalent between the six control subjects and eight MDMA abusers.  In contrast, NK-
cell numbers were significantly decreased in MDMA users, and remained decreased over the 
two-year duration of the study.  One year after the initial observation, the total number of 
lymphocytes, CD4+ T-cells, CD19+ B-lymphocytes were all significantly reduced in MDMA 
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users compared to control subjects.  Moreover, this suppression of leucocyte subpopulations in 
MDMA users became even more apparent two years following the initial observation.  Based 
on these data the authors concluded that permanent alterations in immunological parameters are 
evident in MDMA abusers.  
 
Whilst these non-controlled studies are interesting, the results obtained are somewhat difficult 
to interpret for two reasons.  Firstly, it is not possible to ascertain if the suppression of immune 
parameters observed in the MDMA users is due to MDMA abuse per se.  For instance, it is 
outlined in the methods of the study that the subjects enrolled in the clinical trails were all 
habitual users of cannabis with prior experience of cocaine or methamphetamine [36].  As it is 
well established that cannabis, cocaine and methamphetamine all have significant 
immunomodulatory properties in their own right [1,2,5,6], it is impossible to discount the fact 
that they may have contributed to the immunological changes observed in this experimental 
group.  The second issue pertains to experimental design adopted in the 2 year follow up study.  
In this study the control subjects were not tested at 1 and 2 year intervals, thus comparisons 
were being made using historical data.  For these reasons one must be cautious when 
interpreting these results. 
 
Mechanisms by which MDMA can alter immune function 
Direct effects of MDMA on immune cells: Evidence from in vitro studies 
The molecular targets for MDMA’s action are the transporter (uptake) sites for serotonin and 
dopamine.  Whilst these transporter sites are located predominantly on pre-synaptic 
serotonergic and dopaminergic neurons respectively, there is now ample evidence the cells of 
the immune system also express transporter sites for both of these neurotransmitters [see 
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48,49].  Consequently MDMA can interact directly with immune cells, and thereby has the 
potential to alter their activity directly.    
 
The first study to examine the immunomodulatory potential of MDMA was published almost 
10 years ago by House and co-workers, and examined the impact of in vitro exposure to 
MDMA (0.0001–100M) on a number of immune parameters in splenocytes and peritoneal 
macrophages from B6C3F1 mice [50].  In this study T-cell function was assessed by anti-CD3-
induced IL-2 and IL-4 production, B-cell function was assessed by measuring proliferation, 
natural immunity was assessed by measuring NK-cell cytotoxicity, T-cell effector function was 
evaluated as a function of cytotoxic T-lymphocyte (CTL) activity, and macrophage function 
was assessed by measuring production of the pro-inflammatory cytokines IL-6 and TNF.  In 
vitro exposure to MDMA had no effect on B-cell proliferation.  In terms of T-cell function, 
production of the Th1 cytokine IL-2 was enhanced by 0.0001 M MDMA, suppressed by 
100M MDMA, and not altered by any of the 5 intermediate concentrations.  Production of the 
Th2 cytokine IL-4 was not altered by exposure to any concentration of MDMA examined. 
Basal and IL-2 augmented NK cell cytotoxicity were enhanced at concentrations of MDMA 
between 0.0001 and 0.1 M, however this effect was evident only at one of the three 
effector:target cell ratios employed.  Conversely, IL-2 stimulated NK-cell activity was 
significantly suppressed by MDMA (10 M), but again this effect was evident only at one of 
the three effector:target cell ratios employed in the assay.  CTL induction was significantly 
suppressed at a concentration of 100M, but was unaltered at any of the other concentrations 
used. Finally, LPS-induced macrophage IL-6 or TNF production were not significantly altered 
by any concentration of MDMA, however there was a slight but statistically non-significant 
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suppression of TNF observed at 10 and 100M MDMA.  In summary, the data generated by 
House and co-workers (1995) [50] indicates that in vitro exposure to MDMA has variable, and 
for the most part modest, effects on the immune system depending on the dose employed, and 
the specific immune parameter under investigation.   
 
In a subsequent study Connor et al., (2000) [31] observed that in vitro exposure of LPS-
stimulated diluted rat blood to MDMA failed to mimic its ability to suppress the pro-
inflammatory cytokines IL-1 and TNF-following an in vivo LPS challenge; thereby 
supporting in vitro findings of House et al., (1995) [50].  It was also reported that the ability of 
MDMA to increase LPS-induced IL-10 production in vivo, was not mimicked by in vitro 
exposure of LPS-stimulated diluted whole blood cultures to the drug [28].  In addition, the 
suppressive effect of MDMA on Con A-stimulated lymphocyte proliferation that is observed in 
vivo cannot be mimicked by in vitro exposure to MDMA (Connor, Unpublished observations).  
These data suggest that the potent immunosuppressive actions of MDMA observed following 
in vivo administration are not due to a direct action of the drug on immune cells, and are likely 
to be due to the release of endogenous immunomodulatory substances that occurs in response 
to MDMA.   In contrast to these findings, both in vivo and in vitro exposure to MDMA elicit 
similar suppressive effects on the zymosan-induced oxidative burst in rat neutrophils, 
indicating that MDMA can elicit a direct effect on neutrophil phagocytosis [27].  
 
Indirect mechanisms by which MDMA can impact upon the immune system 
In addition to having a direct effect on immune cells, it is possible that a drug such as MDMA 
that alters neurotransmission within the central nervous system (CNS) could alter 
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immunocompetence via a CNS-mediated mechanism. Specifically, it is well established that 
changes in CNS neurotransmitter function can alter immunity via changes in endocrine output 
and sympathetic nervous system activity [51,52].  MDMA stimulates the release of the 
neurotransmitters serotonin and dopamine in the central nervous system [17,18], and produces 
consequential downstream activation of peripheral immunomodulatory pathways such as the 
hypothalamic pituitary adrenal axis and the sympathetic nervous system [23,53].  Therefore 
when addressing the underlying physiological mechanisms that mediate the 
immunosuppressive effects of MDMA, it is necessary to consider central neurotransmitters that 
drive downstream responses, and also peripheral neurotransmitters and hormones that are the 
ultimate mediators impacting on immune cells.         
 
Central mediators of MDMA-induced immunosuppression 
As the predominant neurochemical action of MDMA is to release serotonin within the CNS, it 
is logical to assume that central serotonin release may mediate the actions of MDMA on the 
immune system.  In this regard it was demonstrated that the related amphetamine compound 
fenfluramine that is a selective releaser of serotonin produced qualitatively similar suppressive 
effects to MDMA on a number of immunological measures in a rats [32,54].  For instance 
fenfluramine suppressed circulating lymphocyte numbers, suppressed T-lymphocyte 
proliferation and cytokine production [32], and also suppressed production of the pro-
inflammatory cytokines IL-1and TNF-in response to an in vivo LPS challenge  [54].  It was 
also of interest that fenfluramine was more potent than MDMA at inducing serotonergic 
changes, and also at provoking immunosuppressive effects  [32].  All of this data pointed 
towards serotonin release as a mediator of the immunosuppressive effects of MDMA in rats.   
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In order to evaluate the role of serotonin in MDMA-induced immunosuppression, two 
pharmacological strategies that inhibit MDMA-induced serotonin release were employed. 
Firstly, the selective serotonin reuptake inhibitor paroxetine was used to prevent MDMA from 
entering serotonergic neurons, thereby preventing MDMA-induced serotonin release [30].  In 
the second study rats were pre-treated with the tryptophan hydroxylase inhibitor p-
chlorophenylalanine (pCPA); an agent that reduces brain serotonin concentrations by 
approximately 90%.  The impact of both of these anti-serotonin strategies on MDMA-induced 
suppression of IL-1  and TNF-  in rats was evaluated.  Whilst paroxetine pre-treatment 
completely blocked MDMA-induced serotonin depletion in both the frontal cortex and 
hypothalamus, it failed to alter the suppressive effects of MDMA on lipopolysaccharide-
induced TNF-  secretion. It was also of interest that paroxetine treatment alone suppressed 
both lipopolysaccharide-induced IL-1  and TNF-  secretion by 27% and 50%, respectively, 
possibly by its ability to increase central serotonin concentrations [30].  The treatment regimen 
of pCPA used caused in excess of a 90% depletion of brain serotonin concentrations. However, 
the suppressive effects of MDMA on LPS-induced IL-1  and TNF-  were equivalent in both 
saline and pCPA-treated groups. In all these data indicated that the immunosuppressive effects 
of MDMA occur by a mechanism(s) independent of serotonin release.  In a similar manner it 
was observed that the suppressive effect of fenfluramine (10 mg/kg) on LPS-induced IL-1 and 
TNF- production were not blocked by pre-treatment with either paroxetine or pCPA [55].  
However in a later study using much lower doses of fenfluramine (1.25 and 2.5 mg/kg), it was 
observed that the suppressive effect of fenfluramine on LPS-induced IL-1production was 
blocked by pre-treatment with pCPA, indicating that it was indeed a serotonin-dependent event 
[56].  In a similar fashion it is also possible that serotonin may contribute to the 
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immunosuppressive effect of low doses of MDMA, and that this may be overridden by 
dopaminergic influences when higher doses are employed.  However, further studies are 
necessary in order to substantiate this hypothesis.  In addition is possible that some aspects of 
MDMA-induced immunosuppression may be serotonin dependent, whilst others may occur by 
a serotonin independent mechanism.   
 
In contrast to the studies outlined above that failed to elucidate a role for serotonin in MDMA-
induced immunosuppression in rats [30], a recent study in humans demonstrated that pre-
treatment with the serotonin reuptake inhibitor paroxetine could block some of the 
immunosuppressive effects of MDMA. Specifically, paroxetine pre-treatment partially 
inhibited that ability of MDMA to suppress circulating CD4+ Thelper cell numbers, and to 
increase circulating NK-cell numbers [35].  In addition, paroxetine totally abolished the 
suppressive effect of MDMA on lymphocyte proliferation and IL-2 production induced by the 
T-cell mitogens Con A and PHA, and blocked the ability of MDMA to enhance PHA-
stimulated production of the anti-inflammatory cytokines IL-10 and TGF-.  In all, these data 
support a role for serotonin release in mediating the suppressive effect of MDMA on human T-
cell function.    
 
In addition to the potent serotonin-releasing properties of MDMA, it is also well established 
that MDMA releases dopamine within the CNS, although with less potency [17,18]. Thus, it is 
possible that dopamine release may play a role in the immunosuppressive effects of MDMA. In 
this regard, it was previously demonstrated that both d-amphetamine and methamphetamine; 
two psychostimulants that are structurally related to MDMA (see Figure 1) and are potent 
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dopamine releasers, elicit immunosuppressive effects in rodents [6,57,58].  Future studies will 
evaluate the role of dopamine in MDMA-induced immunosuppression. 
 
Does behavioural stimulation play a role in the immunosuppressive effect of MDMA ? 
MDMA provokes a variety of euphoric effects in humans and behavioural hyperactivity in 
laboratory animals [see 15].  It is of interest that previous studies demonstrated that depletion of 
serotonin concentrations with p-chlorophenylalanine or blockade of serotonin release by pre-
treatment with SSRI’s attenuate the locomotor stimulant effect of MDMA in rats [19].  
Therefore whilst pretreatment with paroxetine or p-chlorophenylalanine attenuates the 
behavioural effects of MDMA, the immunosuppressive effects (at least on pro-inflammatory 
cytokine production) still persist, indicating a dissociation between the behavioural and 
immunosuppressive effects of MDMA [30]. In addition, the fact that the non-psychostimulant 
amphetamine derivative fenfluramine elicits similar immunosuppressive effects to MDMA 
[32,54,56], supports the view that the psychoactive and immunosuppressive properties of 
substituted amphetamines in rats are not necessarily linked. 
 
A previous study conduced in humans reported that treatment with the SSRI citalopram 
blocked the positive mood, extraversion and self-confidence induced by MDMA [21].  In 
addition, some of the immunosuppressive actions of MDMA in humans are blocked by 
serotonin transporter blockade with the related SSRI paroxetine [35].  However, despite these 
co-incidental effects, the exact role that the euphoric effect of MDMA plays in its ability to 
induce immunosuppression in humans is not clear. 
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Does hyperthermia play a role in the immunosuppressive effect of MDMA ? 
Since MDMA is known to induce hyperthermia it is pertinent to address the possibility that the 
ability of MDMA to alter body temperature could contribute to its immunomodulatory effects.    
However, based on evidence from the published literature it appears unlikely that MDMA-
induced hyperthermia plays a significant role in its immunomodulatory effects.  For instance, 
the ability of MDMA to promote an immunosuppressive cytokine phenotype (reduced TNF- 
and increased IL-10), and a suppression of lymphocyte proliferation are observed at doses as 
low as 1.25 mg/kg [28,33]; a dose that does not alter body temperature [59].  In addition, whilst 
both MDMA and the related amphetamine fenfluramine provoke similar immunosuppressive 
responses in rats, they provoke opposite thermal responses with fenfluramine eliciting a 
hypothermic response [60], and MDMA eliciting a hyperthermic response [23].   
 
Figure 4: A schematic diagram outlining potential central and peripheral mediators of MDMA-
induced immunosuppression
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Peripheral mediators of MDMA-induced immunosuppression: A role for catecholamines or 
glucocorticoids? 
It is well established that MDMA activates both the hypothalamic pituitary adrenal axis and 
sympathetic nervous system [23,33,53], and that the end products of these axes namely 
glucocorticoids and catecholamines have immunosuppressive properties [61,62].  Therefore it 
was plausible to suggest that MDMA could elicit its immunosuppressive actions by increasing 
the release of these endogenous negative immunoregulators.  Consistent with this hypothesis, it 
was demonstrated that the increase in IL-10 induced by MDMA could be blocked by pre-
treatment with the -adrenoceptor antagonists propranolol and nadolol, indicating that the 
MDMA-induced enhancement of IL-10 production was mediated by -adrenoceptor activation, 
presumably in response to MDMA-induced catecholamine release [28].  In contrast, the 
suppression of pro-inflammatory cytokines TNF- and IL-1 induced by MDMA occurred 
independent of -adrenoceptor activation [28].  However the possibility still exists that 
catecholamines may mediate the suppression of pro-inflammatory cytokines induced by 
MDMA by acting on other adrenoceptor subtypes such as the 1-adrenoceptor. 
 
With respect to the role of glucocorticoids in MDMA-induced immunosuppression, it was 
observed that pre-treatment of rats with the glucocorticoid receptor antagonist mifepristone 
failed to block the suppressive effect of MDMA on LPS-induced IL-1 and TNF- production 
(Connor, unpublished data).  Moreover in a recent study it was observed that adrenalectomy 
failed to block the ability of MDMA to suppress TNF-and increase IL-10 production [28].  
These data clearly demonstrate that glucocorticoids do not mediate the ability of MDMA to 
promote an immunosuppressive cytokine phenotype in rats.  However further studies are 
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required to determine if glucocorticoids play a role in the suppressive effect of MDMA on 
other immunological parameters such as mitogen stimulated T-cell responses, or antigen-
specific T-cell responses and antibody production. 
 
The fact that MDMA maintained the ability to increase LPS-induced IL-10 production in 
adrenalectomized rats indicates that this response is not mediated by adrenal catecholamines, 
suggesting that noradrenaline may modulate LPS-induced IL-10 production by direct 
innervation of immune organs such as the spleen.  Studies are currently underway to investigate 
this possibility.   In contrast to the animal studies, to date there has been a paucity of research 
with respect to peripheral mediators of MDMA-induced immunosuppression in humans.  
Whilst it has been demonstrated that MDMA activates the hypothalamic pituitary adrenal axis 
and sympathetic nervous system in humans [39,53], the effect of glucocoticoid receptor 
antagonists/synthesis inhibitors or adrenoceptor antagonists have not been examined in human 
studies.  
 
A role for peripheral serotonin or dopamine in the immunosuppressive actions of MDMA ? 
 
Serotonin 
Immune cells have ample opportunity to be exposed to serotonin that is released from platelets 
in the periphery [see 48].   In addition to platelet-derived serotonin, it was previously suggested 
that sympathetic nerve terminals in lymphoid tissues take up serotonin, which can be released 
upon later stimulation of these nerves [49].  Moreover, it is well established that serotonin 
receptors are present on a variety of immune cells [see 48,49], and that serotonin has 
immunomodulatory properties, with some studies indicating that it enhances, and others 
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indicating that it suppresses, aspects of immune function [63,64,65].  However, despite the 
immunomodulatory potential of serotonin, there is no evidence to suggest that MDMA releases 
serotonin from peripheral stores.  In fact the few studies that have examined the impact of 
MDMA on platelet or plasma serotonin concentrations have not observed any change following 
MDMA administration [66,67].   
 
Dopamine 
Catecholamines, including dopamine, are present in lymphocytes, macrophages and 
neutrophils; the first two of which have been shown capable of synthesising dopamine [see 48].  
In addition, noradrenergic sympathetic fibres in the spleen can take up circulating dopamine 
particularly during stress, which may then be released on sympathetic activation, and act upon 
immune cells in the vicinity of release [see 48].  Thus immune cells can come in contact with 
dopamine in the periphery.  From a functional perspective a number of studies have 
demonstrated the presence of dopamine receptors on various immune cells, and indicate that 
dopamine has immunosuppressive properties [68-71].  However despite these findings the 
impact of MDMA on dopamine release in the periphery has not been studied, and therefore 
although dopamine has immunosuppressive properties it is difficult to say if it plays a role in 
MDMA-induced immunosuppression.   
 
Thus further studies are required in order to determine if peripheral serotonin or dopamine play 
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MDMA abuse – A stressor on the immune system 
As many of the physiological changes elicited by MDMA closely resemble those induced by 
psychological or physical stress, it is suggested that exposure to MDMA could be regarded as a 
“chemical stressor” on the immune system.  Exposure to stress is known to provoke similar 
immunological changes in both in laboratory animals and in man to those induced by MDMA.  
For instance, acute stress promotes an immunosuppressive cytokine phenotype in response to 
LPS [72,73].  Stress also suppresses lymphocyte proliferation and promotes a Th2 type 
cytokine response [74-79], and increases circulating NK-cell numbers [79-81].   
 
Does MDMA-induced immunosuppression translate into a significant health risk for 
abusers? 
 
Based on the studies outlined above, it is clear that MDMA suppresses both innate and adaptive 
immunity in animals and humans.  Therefore it is possible the immunosuppressive effects of 
MDMA could lead to an abnormal immune response at times of infection or illness.  For 
instance, pre-clinical studies have demonstrated that a deficiency in pro-inflammatory 
cytokines such as IL-1 or TNF- can have a significant impact on host resistance to infectious 
disease.  Specifically, TNF- knockout mice have reduced host resistance to Listeria 
monocytogenes infection [82], and antagonism of IL-1 receptors with IL-1ra interferes with 
host resistance to infection with Mycobacterium avium [83].  In addition, considering the 
important role of Th1-driven IgG2a antibody production in antiviral immunity [see 29], it is 
possible that MDMA abuse could interfere with reduce host resistance to viral infections.  Also 
the long-term depletion in NK-cell numbers reported following MDMA abuse in humans gives 
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rise to concern considering the important role that NK-cells play in cell-mediated immunity, 
and more particularly in tumour surveillance [84,85].  Having all this said, it is difficult to 
predict the impact of MDMA-induced immunosuppression on disease susceptibility, as we 
don’t know what degree of functional reserve is present within the immune system, and also as 
there are no data available regarding the impact of MDMA administration on host resistance in 
infection models.  However, it was previously demonstrated that administration of d-
amphetamine the parent compound of MDMA reduced host resistance to infection by influenza 
A virus and the bacteria Listeria monocytogenes [11,57]. Nonetheless, studies examining 
susceptibility to bacterial/viral infections are required in order to determine as to whether 
impairments in innate and adaptive immunity induced by MDMA have a major impact on 
infectivity and disease progression. 
 
There are very few studies in the clinical literature that have examined the incidence of 
infections in MDMA abusers.  However one recent report presented the results of a survey of 
282 Ecstasy users that participated in a WWW study [86].   The sample was comprised of 109 
novice users (1-9 occasions), 136 moderate users (10-99 occasions), and 36 heavy users (+100 
occasions). In this study yes/no responses were recorded to a series of questions covering 
problems experienced when drug-free which were attributed by the respondents to their Ecstasy 
use. In this survey, infections were cited as one of the problems that were significantly 
associated with the extent of Ecstasy use [86]. In addition, there have been cases where MDMA 
abuse in humans closely preceded the development of meningococcal meningitis [87].   
 
It is also possible that both the environment in which MDMA is consumed, and/or the 
psychoactive effects that MDMA induces, could synergise with the immunosuppressive effects 
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of the drug, to result in increased susceptibility to infectious disease.  For instance MDMA use 
has traditionally been associated with the rave dance club scene; a crowded and environment 
where teenagers congregate.  Such an environment is optimal for transmitting airborne 
infection between individuals.  In addition, the results of a recent study indicated that MDMA 
abuse was strongly and significantly associated with high-risk sexual behaviors (unprotected 
anal intercourse) in a population of gay/bisexual men sampled from three New York dance 
clubs [88].  Thus when one combines such environmental factors with the immunosuppressive 
effect of MDMA, it is reasonable to suggest that MDMA users may have a higher risk of 
developing infectious disease in comparison to drug-free subjects.   
 
Conclusions 
Research conducted over the last five years has clearly demonstrated that administration of 
MDMA to both animals and humans has profound immunosuppressive effects; a property that 
it shares with other drugs of abuse [1-6].  For the most part the immunosuppressive effects of 
MDMA are not due to a direct action of the drug on immune cells, but rather due to the release 
of endogenous immunomodulatory substances, and it is suggested that exposure to MDMA 
could be regarded as a “chemical stressor” on the immune system.  Further studies are required 
in order to elucidate the central and peripheral mediators of MDMA-induced 
immunosuppression.  In addition, assessment of the effect of MDMA in pre-clinical host 
resistance models, and further clinical research is required before any definitive statement can 
be made on the propensity of MDMA-induced immunosuppression to translate into increased 
disease susceptibility.  
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